Price$165.88+0.69 (+0.42%)
01:30 PM07:45 PM
News · 26 weeks103-14%
2026-03-012026-08-23
Mix5190d
- SEC Filings26(51%)
- Other20(39%)
- Insider3(6%)
- Analyst1(2%)
- Earnings1(2%)
Latest news
25 items- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- PRMost AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.NEW YORK, Aug. 19, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary - Artificial intelligence has become the most talked-about tool in drug discovery, promising to compress the years and billions of dollars it takes to turn a biological insight into a medicine. But most of the AI now aimed at biology shares a hidden limitation: it reasons primarily from sequence, the raw genetic letters of DNA, RNA, and proteins. Two molecules whose sequences look alike are treated as related; two that look different are treated as unrelated. That assumption is convenient, and it is often wrong, because biology repeatedly reaches the same function through completely different-looking structures. A c
- PRENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trialAstraZeneca and Daiichi Sankyo’s ENHERTU is the first and only HER2-directed medicine to improve progression-free survival over global standard of care in a Phase III trial in this setting Positive high-level results from the DESTINY-Lung04 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus global standard of care (platinum-pemetrexed doublet chemotherapy plus pembrolizumab) as 1st-line treatment of patients with unresectable, locally advanced or metastatic HER2-mutant non-squamous non-small cell lung cancer (NSCLC). The trial will continue as planned to
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- PRTAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSOFirst global Phase III trial to show significant progression-free and overall survival benefits in this setting SAFFRON trial results reinforce TAGRISSO as the backbone therapy across EGFRm lung cancer Positive high-level results from the SAFFRON Phase III trial showed TAGRISSO® (osimertinib) plus savolitinib demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and overall survival (OS) versus doublet platinum-based chemotherapy in patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). Patients in the trial had tumors with high levels of MET overexpression or amplification and h
- PREnhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 TrialDaiichi Sankyo and AstraZeneca’s Enhertu is the first and only HER2 directed medicine to improve progression-free survival over global standard of care in a phase 3 trial in this setting Data to be presented at an upcoming medical meeting and shared with global regulatory authorities Positive topline results from the DESTINY-Lung04 phase 3 trial showed Enhertu® (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus global standard of care (platinum-pemetrexed doublet chemotherapy plus pembrolizumab) as first-line treatment of patients with unresectable, locally advanced or metastatic HER2 mutan
- INSIDERSVP, Group Controller Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,267 units (SEC Form 4)4 - ASTRAZENECA PLC (0000901832) (Issuer)
- PRSOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology TherapiesBOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (NYSE:AZN). This multi-year collaboration agreement will advance the development and commercialization of two companion diagnostic programs, bringing SOPHiA GENETICS's decentralized clinical trial assays and companion diagnostic capabilities to AstraZeneca therapies. As part of the collaboration, SOPHiA GENETICS will develop its Solid Tumor application into a decentralized comp
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- PRDatroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for ImmunotherapyApproval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- PRSonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancersResults provide opportunity to expand CLDN18.2 positivity to ≥25% expression, representing approximately 60% of patients in this setting CLARITY-Gastric01 is the first Phase III trial to show overall survival benefit with an anti-CLDN18.2 ADC in this setting First pivotal readout from AstraZeneca’s wholly owned ADC portfolio Positive high-level results from the CLARITY-Gastric01 global Phase III trial showed that sonesitatug vedotin (Sone-Ve) demonstrated a statistically significant and highly clinically meaningful improvement in overall survival (OS) in 2nd and later-line Claudin 18.2-positive advanced gastric cancers versus investigator’s choice of therapy. The trial included patien
- PRAstraZeneca results: H1 and Q2 2026Growth momentum continues. On track to deliver ambition of $80 billion in Total Revenue in 2030 AstraZeneca: Revenue and EPS summary H1 2026 % Change Q2 2026 % Change $m Actual CER1 $m Actual CER - Product Sales 28,896 8 5 14,510 5 4 - Alliance Revenue 1,699 31 29 874 34 33 Product Revenue 30,595 9 6 15,384 6 5 Collaboration Revenue 77 (6) (9) - n/m n/m Total Revenue 30,672 9 6 15,384 6 5
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- PREnhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast CancerRecommendation based on DESTINY-Breast09 phase 3 trial results that showed Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP with a median progression-free survival exceeding three years If approved, Daiichi Sankyo and AstraZeneca’s Enhertu plus pertuzumab would become first new treatment in the EU in more than a decade for first-line HER2 positive metastatic breast cancer Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been recommended for approval in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- ANALYSTAstraZeneca downgraded by HSBC SecuritiesHSBC Securities downgraded AstraZeneca from Buy to Hold
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- INSIDEROfficer Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,265 units (SEC Form 4)4 - ASTRAZENECA PLC (0000901832) (Issuer)
AZN FAQ
8 questionsWhat does AstraZeneca PLC do?
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir...Where does AZN stock trade?
AstraZeneca PLC (AZN) is listed on NYSE.What sector and industry is AZN in?
AstraZeneca PLC operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did AstraZeneca PLC go public?
AstraZeneca PLC (AZN) completed its IPO in 2026.Does AZN pay a dividend?
AZN's most recent ex-dividend date was 2026-08-07 with a cash dividend of $1.06 per share. No future ex-date is on file yet.What are analysts saying about AZN?
AstraZeneca PLC has had 8 recent analyst actions on file. The most recent action was from HSBC Securities: Hold on 2026-07-13.What companies are similar to AZN?
Notable peers in the same industry include JNJ (Johnson & Johnson), MRK (Merck & Company Inc.), NVS (Novartis AG), PFE (Pfizer Inc.), BMY (Bristol-Myers Squibb Company). Compare AZN side-by-side with any of them on Quantisnow.How can I track AZN on Quantisnow?
Quantisnow aggregates AstraZeneca PLC's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AZN to receive live email and push alerts on every new disclosure.